Payment Options
Cash App
Apple Pay
PayPal
Crypto (USDC)
$10 USPS Priority Shipping
Estimated delivery: 2–5 business days. Delivery times may vary.
Orders of $500 or more ship free. Final shipping details at checkout.
Survodutide — 10 mg
$79.49
Survodutide, also called BI 456906, is a dual GLP-1/glucagon receptor agonist developed for metabolic research. Its clinical program examines body weight and liver disease, combining incretin-related effects with glucagon-receptor activity. For research use only; not for human or veterinary use.
Full description
Educational research context. The cited studies and supplier descriptions do not verify the identity, testing, or effects of this Heritage product.
Survodutide is a peptide developed by Boehringer Ingelheim and Zealand Pharma to activate both GLP-1 and glucagon receptors. It differs from tirzepatide, which targets GIP and GLP-1, and from retatrutide, which adds all three receptor activities. Umbrella presents survodutide as a research compound associated with obesity and liver-disease studies, using BI 456906 as an alternate identifier.
A randomized phase 2 obesity trial reported dose-dependent body-weight reductions over 46 weeks. The largest planned-treatment group reduction was approximately 15%, compared with roughly 3% for placebo; gastrointestinal events were common. These results explain the product’s positioning around weight and metabolic research, while showing why the study population and analysis method matter when comparing promotional figures. The seller also refers to liver-fat research. The clinical results concern defined investigational formulations and should be distinguished from the characteristics or performance of an independently sold research vial.
Sources
- Umbrella Labs — product description (captured page)Supplier listing (not independent scientific evidence)
- Survodutide phase 2 obesity trialLiterature record (study type requires review)
For research use only. Not for human or veterinary use; not medical advice.